Apr 22, 2015 8:00 am EDT CymaBay Therapeutics Announces U.S. Orphan Drug Designation for MBX-8025 in Severe Hypertriglyceridemia
Apr 20, 2015 8:00 am EDT CymaBay Therapeutics Strengthens Management Team With the Appointment of Kirk Rosemark to VP, Regulatory Affairs and Quality Assurance
Mar 25, 2015 8:00 am EDT CymaBay Therapeutics Announces U.S. Orphan Drug Designation for MBX-8025 in Homozygous Familial Hypercholesterolemia
Mar 23, 2015 10:00 am EDT CymaBay Therapeutics to Host Key Opinion Leader Meeting on March 27 in New York City
Mar 11, 2015 8:00 am EDT CymaBay Therapeutics to Announce Fourth Quarter and Year-End 2014 Financial Results and Business Update on Wednesday, March 18, 2015
Feb 24, 2015 6:00 am EST CymaBay Therapeutics Announces Positive Results From Its Phase 2b Clinical Study Demonstrating That Arhalofenate Met the Primary Endpoint of Reduction in Gout Flares